 |
|
|
| |
Simeprevir (TMC435) in combination with peginterferon and ribavirin for treatment of HCV genotype 1 infection in treatment-naïve and -experienced patients (PILLAR and ASPIRE Trials)
|
| |
| |
Reported by Jules Levin
IDSA Oct 17-21 2012 San Diego
Ira Jacobson, MD,1 Michael Fried, MD,2 Peter Ferenci, MD,3 Igor Nikitin, MD,4
Fred Poordad, MD,5 Stefan Zeuzem, MD,6 Oliver Lenz, PhD,7 Vanitha Sekar, PhD,8
Monika Peeters, MSc,7 Goedele De Smedt, MD,7 and Maria Beumont-Mauviel, MD7
(1) Weill Medical College of Cornell University, New York, NY, USA; (2) University of North Carolina at Chapel Hill, Chapel Hill, NC, USA;
(3) Allgemeines Krankenhaus der Stadt Wien, Vienna, Austria; (4) Russian State Medical University, Moscow, Russia; (5) Cedars-Sinai Medical Center, Los Angeles, CA, USA; (6) Gastroenterology, Klinikum der Johann-Wolfgang-Goethe-Universitat-Med. Klinik I, Frankfurt, Germany;
(7) Janssen Infectious Diseases BVBA, Beerse, Belgium; (8) Janssen Research and Development LLC, Titusville, NJ, USA
IDSA: The Pharmacokinetic Interactions of the HCV Protease Inhibitor Simeprevir (TMC435) With HIV Antiretroviral Agents in Healthy Volunteers - (10/19/12)
|
| |
|
|
|
|
|
